Loading...

Fluicell

OM:FLUI
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FLUI
OM
SEK65M
Market Cap
  1. Home
  2. SE
  3. Healthcare
Company description

Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • Fluicell has significant price volatility in the past 3 months.
FLUI Share Price and Events
7 Day Returns
-4.6%
OM:FLUI
2.5%
SE Medical Equipment
2.2%
SE Market
1 Year Returns
-
OM:FLUI
26.8%
SE Medical Equipment
3.7%
SE Market
FLUI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Fluicell (FLUI) -4.6% 5.4% 30.6% - - -
SE Medical Equipment 2.5% -0.7% 15.5% 26.8% 24.3% 11.4%
SE Market 2.2% 1.5% 11.5% 3.7% 12.6% 23.1%
1 Year Return vs Industry and Market
  • No trading data on FLUI.
  • No trading data on FLUI.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Fluicell undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Fluicell. This is due to cash flow or dividend data being unavailable. The share price is SEK8.683.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Fluicell's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Fluicell's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OM:FLUI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-2.12
OM:FLUI Share Price ** OM (2019-03-19) in SEK SEK8.68
Sweden Medical Equipment Industry PE Ratio Median Figure of 12 Publicly-Listed Medical Equipment Companies 39.19x
Sweden Market PE Ratio Median Figure of 322 Publicly-Listed Companies 16.99x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Fluicell.

OM:FLUI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:FLUI Share Price ÷ EPS (both in SEK)

= 8.68 ÷ -2.12

-4.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fluicell is loss making, we can't compare its value to the SE Medical Equipment industry average.
  • Fluicell is loss making, we can't compare the value of its earnings to the Sweden market.
Price based on expected Growth
Does Fluicell's expected growth come at a high price?
Raw Data
OM:FLUI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Sweden Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2.08x
Sweden Market PEG Ratio Median Figure of 234 Publicly-Listed Companies 1.31x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Fluicell, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Fluicell's assets?
Raw Data
OM:FLUI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK3.12
OM:FLUI Share Price * OM (2019-03-19) in SEK SEK8.68
Sweden Medical Equipment Industry PB Ratio Median Figure of 42 Publicly-Listed Medical Equipment Companies 4.14x
Sweden Market PB Ratio Median Figure of 562 Publicly-Listed Companies 2.46x
OM:FLUI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:FLUI Share Price ÷ Book Value per Share (both in SEK)

= 8.68 ÷ 3.12

2.78x

* Primary Listing of Fluicell.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fluicell is good value based on assets compared to the SE Medical Equipment industry average.
X
Value checks
We assess Fluicell's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Fluicell has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Fluicell expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fluicell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Fluicell expected to grow at an attractive rate?
  • Unable to compare Fluicell's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Fluicell's earnings growth to the Sweden market average as no estimate data is available.
  • Unable to compare Fluicell's revenue growth to the Sweden market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OM:FLUI Future Growth Rates Data Sources
Data Point Source Value (per year)
Sweden Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 34%
Sweden Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 10%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 8.5%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OM:FLUI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OM:FLUI Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -12 -15
2018-09-30 2 -12 -12
2018-06-30 2 -10 -11
2018-03-31 1 -6 -9
2017-12-31 1 -8 -7
2016-12-31 3 -5 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Fluicell is high growth as no earnings estimate data is available.
  • Unable to determine if Fluicell is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OM:FLUI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Fluicell Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:FLUI Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -2.12
2018-09-30 -1.62
2018-06-30 -1.43
2018-03-31 -1.64
2017-12-31 -1.43
2016-12-31 -1.51

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Fluicell will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Fluicell's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Fluicell's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Fluicell's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Fluicell's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Fluicell has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Fluicell performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Fluicell's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Fluicell does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Fluicell's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Fluicell's 1-year growth to the SE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Fluicell's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Fluicell Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:FLUI Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.23 -14.70 15.29
2018-09-30 1.85 -12.10 13.05
2018-06-30 1.58 -10.68 11.47
2018-03-31 1.28 -8.69 9.18
2017-12-31 1.05 -7.47 7.84
2016-12-31 2.64 -4.95 6.02
2015-12-31 1.06 -2.84 2.36
2014-08-31 0.14 -1.65 1.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Fluicell has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Fluicell has efficiently used its assets last year compared to the SE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Fluicell improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Fluicell's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Fluicell has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Fluicell's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Fluicell's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Fluicell is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Fluicell has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Fluicell's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Fluicell has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Fluicell Company Filings, last reported 2 months ago.

OM:FLUI Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 23.37 0.00 22.23
2018-09-30 28.11 0.00 26.29
2018-06-30 31.63 0.00 29.93
2018-03-31 36.37 0.04 5.04
2017-12-31 9.58 0.07 7.83
2016-12-31 1.84 0.22 1.10
2015-12-31 0.69 0.37 0.75
2014-08-31 1.19 0.23 1.14
  • Fluicell has no debt.
  • Fluicell currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Fluicell has sufficient cash runway for 1.6 years based on current free cash flow.
  • Fluicell has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 43.9% each year.
X
Financial health checks
We assess Fluicell's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Fluicell has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Fluicell's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Fluicell dividends.
If you bought SEK2,000 of Fluicell shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Fluicell's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Fluicell's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OM:FLUI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Sweden Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.1%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 247 Stocks 3.6%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1.2%
Sweden Bottom 25% Dividend Yield 25th Percentile 1.9%
Sweden Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Fluicell has not reported any payouts.
  • Unable to verify if Fluicell's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Fluicell's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Fluicell has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Fluicell's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Fluicell afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Fluicell has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Fluicell's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Victoire Viannay
AGE 43
TENURE AS CEO 2.2 years
CEO Bio

Ms. Victoire Viannay has been Chief Executive Officer at Fluicell AB (publ) since 2017. Previously, Ms. Viannay served as the Chief Operating Officer of Fluicell AB. Former Legal & HR Assistant Manager at Institut Curie, former Project Leader at Chalmers University of Technology, former Chief HR and Legal Officer at PSL Research University, she has more than 10 years of experience in labor laws, human resources and legal management, particularly in the field of scientific research. She holds a PhD in Law from Université Paris II Panthéon/Assas.

CEO Compensation
  • Insufficient data for Victoire to compare compensation growth.
  • Insufficient data for Victoire to establish whether their remuneration is reasonable compared to companies of similar size in Sweden.
Management Team Tenure

Average tenure and age of the Fluicell management team in years:

2.2
Average Tenure
43
Average Age
  • The tenure for the Fluicell management team is about average.
Management Team

Victoire Viannay

TITLE
Chief Executive Officer
AGE
43
TENURE
2.2 yrs

Mats Jonasson

TITLE
Chief Financial Officer
AGE
62
TENURE
3.2 yrs

Gavin D. Jeffries

TITLE
CTO & Director
AGE
38
TENURE
2.2 yrs

Tatsiana Lobovkina

TITLE
Chief Scientific Officer
AGE
43
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Fluicell board of directors in years:

3.2
Average Tenure
46
Average Age
  • The tenure for the Fluicell board of directors is about average.
Board of Directors

Stefan Tilk

TITLE
Chairman of the Board
AGE
54
TENURE
3.2 yrs

Gavin D. Jeffries

TITLE
CTO & Director
AGE
38
TENURE
7.2 yrs

Owe Orwar

TITLE
Director
AGE
54
TENURE
4.2 yrs

Daniel Chiu

TITLE
Director
AGE
46
TENURE
2.2 yrs

Carl Fhager

TITLE
Director
AGE
43
TENURE
2.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
08. Jun 18 Buy Owe Orwar Individual 05. Jun 18 08. Jun 18 1,500 SEK14.58 SEK21,011
18. May 18 Buy Owe Orwar Individual 16. May 18 18. May 18 1,750 SEK12.09 SEK20,020
X
Management checks
We assess Fluicell's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Fluicell has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Type Of Shareholder Owns Fluicell AB (publ)'s (STO:FLUI)?

A look at the shareholders of Fluicell AB (publ) (STO:FLUI) can tell us which group is most powerful. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … With a market capitalization of kr67m, Fluicell is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Breaking Down Fluicell AB (publ)'s (STO:FLUI) Ownership Structure

Today, I will be analyzing Fluicell AB (publ)’s (STO:FLUI) recent ownership structure, an important but not-so-popular subject among individual investors. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … Therefore, it is beneficial for us to examine FLUI's ownership structure in more detail.

Simply Wall St -

Who Are Fluicell AB (publ)'s (STO:FLUI) Major Shareholders?

Check out our latest analysis for Fluicell OM:FLUI Ownership_summary May 22nd 18 Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … Private Company Ownership Potential investors in FLUI should also look at another important group of investors: private companies, with a stake of 14.88%, who are primarily invested because of strategic and capital gain interests. … An ownership of this size indicates a strong financial backing and has the potential to influence FLUI's business strategy.

Simply Wall St -

Fluicell AB (publ) (STO:FLUI): Does The Earnings Decline Make It An Underperformer?

Understanding how Fluicell AB (publ) (OM:FLUI) is performing as a company requires looking at more than just a years' earnings. … Today I will run you through a basic sense check to gain perspective on how Fluicell is doing by comparing its latest earnings with its long-term trend as well as the performance of its medical equipment industry peers. … I prefer to use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data.

Simply Wall St -

Company Info

Description

Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.

Details
Name: Fluicell AB (publ)
FLUI
Exchange: OM
Founded: 2012
SEK64,991,994
7,484,970
Website: http://www.fluicell.com
Address: Fluicell AB (publ)
Biotech-Huset, vån 7,
Arvid Wallgrens Backe 20,
Gothenburg,
Västra Götaland County, 413 46,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM FLUI Share Capital OMX Nordic Exchange Stockholm SE SEK 18. Apr 2018
Number of employees
Current staff
Staff numbers
0
Fluicell employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/19 22:17
End of day share price update: 2019/03/19 00:00
Last earnings filing: 2019/02/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.